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Amyotrophic lateral sclerosis (ALS) is a
neurodegenerative disease in which the
motor neurons of the central nervous
system—those cells of the brain and spinal
cord that control muscles—die off. The
resulting paralysis typically leads to death
within 3–5 years of onset. The cause of the
disease in the majority of cases is complete-
ly unknown, and there is no treatment that
halts or significantly slows the disease. In
the United States ALS is often known as
Lou Gehrig’s Disease, after the baseball
player who famously suffered from it.
Several genes have been linked to ALS.
The most recent, called FUS (fused in
sarcoma, a reference to the context of its
discovery), is the subject of two new studies
in this issue of PLoS Biology, one by Zhihui
Sun, Zamia Diaz, James Shorter, Aaron
Gitler, and colleagues, and the other by
Shulin Ju, Gregory Petsko, Dagmar Ringe,
and colleagues. Both explore FUS biology in
yeast, and highlight the potential for mod-
eling elements of complex diseases in this
simplest of eukaryotic cell systems. Results
from both studies suggest that defects in
RNA processing and transport may be a
central element of ALS pathophysiology.
Within the cytoplasm of motor neurons
in ALS patients, proteins aggregate to form
insoluble clumps, called inclusions, which
can include both FUS and another ALS-
causing protein, called TDP-43. When the
two research groups overexpressed human
FUS in yeast, they observed cytoplasmic
inclusions. Inclusions form in most of the
neurodegenerative diseases, including Alz-
heimer’s disease and Parkinson’s disease,
suggesting that common defects in protein
handling may link all of them.
In humans, FUS is found predominantly
in the nucleus, and at least some ALS-
associated mutations reduce the nuclear/
cytoplasmic ratio of the protein, suggesting
that its mislocalization to the cytoplasm,
rather than mutation per se, may be an
important step in disease pathogenesis.
Supporting that hypothesis, both groups
found that restricting overexpressed wild-type
FUS to the nucleus mitigated its toxic effect.
Both FUS and TDP-43 are RNA-
binding proteins. But Sun et al. found
that purified FUS is far more prone to
aggregation than purified TDP-43, and
both groups showed that the molecular
features that are critical for aggregation
differed between the two proteins, which
may indicate that the disease-causing
mechanism also differs between them,
despite their broadly similar functions.
Both groups conducted genome-wide
screens to identify genes that specifically
mitigate toxicity. Gratifyingly, despite
differences in lab and protocol details,
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Superimposed on a picture of Lou Gehrig at bat is an image of a yeast model of
proteotoxicity in the disease that bears his name. Human FUS/TLS, normally found in
the nucleus (blue), is mislocalized as punctate cytoplasmic inclusions (green), just as
in some cases of Lou Gehrig’s Disease.
doi:10.1371/journal.pbio.1001053.g001
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sets of candidates, suggesting these genes
play central roles in bypassing whatever
the toxic pathways are. The handful of
identified genes included ones coding for
other DNA/RNA binding proteins. One,
called ECM32, has a human homolog,
hUPF1, that Ju et al. found also rescued
toxicity. One function of hUPF1 is in
messenger RNA quality control, strength-
ening the case that RNA handling is
defective in FUS-caused ALS. Interesting-
ly, expression of hUPF1 was able to rescue
FUS toxicity in yeast without driving FUS
out of the inclusions or sending it back to
the nucleus, suggesting that it may be
possible to overcome the effects of mis-
localized FUS therapeutically without
solving the difficult problem of restoring
it to its proper compartment.
These two studies have at least two
important consequences. By identifying
new genes that can lessen ALS-linked
toxicity, they point the way to exploration
of new therapeutics based on RNA
processing. Perhaps just as importantly,
they demonstrate that yeast has the
potential to be a versatile system for
modeling aspects of ALS that previously
have only been modeled in mice. Since
testing ideas about pathogenesis and
treatment is much faster and cheaper in
yeast, these results may open the way for
more rapid progress in understanding the
disease, its treatment, and the role of this
new gene in ALS development.
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